| Literature DB >> 36003539 |
Xinyu Wang1,2, Vincent Chan1, Peter R Corridon2,3.
Abstract
Vascular diseases contribute to intensive and irreversible damage, and current treatments include medications, rehabilitation, and surgical interventions. Often, these diseases require some form of vascular replacement therapy (VRT) to help patients overcome life-threatening conditions and traumatic injuries annually. Current VRTs rely on harvesting blood vessels from various regions of the body like the arms, legs, chest, and abdomen. However, these procedures also produce further complications like donor site morbidity. Such common comorbidities may lead to substantial pain, infections, decreased function, and additional reconstructive or cosmetic surgeries. Vascular tissue engineering technology promises to reduce or eliminate these issues, and the existing state-of-the-art approach is based on synthetic or natural polymer tubes aiming to mimic various types of blood vessel. Burgeoning decellularization techniques are considered as the most viable tissue engineering strategy to fill these gaps. This review discusses various approaches and the mechanisms behind decellularization techniques and outlines a simplified model for a replacement vascular unit. The current state-of-the-art method used to create decellularized vessel segments is identified. Also, perspectives on future directions to engineer small- (inner diameter >1 mm and <6 mm) to large-caliber (inner diameter >6 mm) vessel substitutes are presented.Entities:
Keywords: bioartificial; blood vessel; decellularization; recellularization; vascular replacement therapy; vascular tissue engineering
Year: 2022 PMID: 36003539 PMCID: PMC9394443 DOI: 10.3389/fbioe.2022.951644
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
A systematic summary of decellularization methods, their mechanisms of actions, and related references.
| Decellularization technique | Mechanisms of action | References | |
|---|---|---|---|
| Physical treatments | Free-thaw cycle | Thermal shock generated from repeated freezing and thaw cycles ruptures membranes |
|
| High hydrostatic pressure | Cold isostatic pressure disrupts cellular membranes within tissues |
| |
| Electroporation | Microsecond- durational electrical pulses to enhance the cellular membrane permeability drastically |
| |
| Supercritical fluid | Gases/liquids exist above critical pressure/temperature eliminate cell compartments within tissues |
| |
| Subcritical fluid | Liquefied (subcritical) DME extracts lipids of tissues |
| |
| Immersion and agitation | Immerse tissues in chambers with decellularizing agents, and agitate tissues with a magnetic plate, ultrasound source, shaker, or an agitator attached to the end of the chamber. |
| |
| Perfusion | The fluid (agent solution) passage through the circulation system to tissues/organs |
| |
| Chemical treatments | Acids and bases | Bases hydrolyze proteins to promote cellular debasement and acids lead to denaturation and protein function loss |
|
| Surfactants (ionic, non-ionic and zwitterionic) | Lyse cell membranes through protein crystallization, destabilizing, denaturing, targeting lipid-lipid interactions |
| |
| Chaotropes | Chaotropic agents disrupt the hydrogen bonding networks, van der Waals forces, and hydrophobic effects |
| |
| Osmotic stress | Hypertonic/hypotonic solution-induced osmotic stress/shock responses disrupt cell stability and interfere with the interaction between DNA and proteins |
| |
| Biologic treatments | Enzymatic approach | Enzyme-based processes that disrupt the bonds and interactions between nucleic acids and interacting cells through the disruptions of neighboring proteins and other cellular components. |
|
| Combination of physical/chemical/enzymatic treatments | Physical, chemical, and enzymatic treatments are combined to optimize vascular decellularization |
| |
A summary of commercially available decellularized vascular products, their associated applications, and clinical performance.
| Vascular product | Product information | Approved indications | Clinical applications | Product advantages/Disadvantages |
|---|---|---|---|---|
| Artegraft®: bovine carotid artery( | Decellularized steer’s carotid artery through physical and chemical treatments; ID: 4–8 mm; length:15–50 cm | Distal/segmental aorta replacement, arterial bypass/patch graft, arteriovenous shunt, and femoropopliteal bypass in lieu saphenous vein | Hemodialysis arteriovenous fistula grafting, salvage and repair, and lower extremity arterial trauma bypass | Reduced thrombus and patency rates compared to ePTFE, good saturability, and collagen matrix retains native cross-weave pattern with natural biocompatibility products available in multiple sizes to match host vessels |
| Cryovein®: human femoral vein ( | Small diameter grafts such as cryopreserved saphenous vein allografts | Saphenous veins, femoral veins, and femoral arteries for salvaging a localized prosthetic graft infection | Hemodialysis applications and extended lengths used to treat acutely ischemic limbs | Promising short-term, but extended thrombosis, poor 1-year patency, and aneurysmal degeneration led to rupture, calcification, and limited use |
| Cytograft, LifelineTM ( | Vascular graft is a living conduit with the properties of a native vessel | Self-assembled cell-sheet of human fibroblast in a shape of vascular conduit | Arteriovenous shunt for hemodialysis | ECs were seeded in graft after devitalization, and constructed using patient cells, void of synthetic or exogenous material, but requires 6–9-month production time |
| Humacyte® ( | Polyglycolic acid biodegradable scaffold with SMCs from deceased organ and tissue donors | Resulting bioengineered vessel is then decellularized to create conduit | Conducted its phase II clinical trials in patients with end-stage renal disease | 63% permeability 6 months after implantation (in 60 patients), absence of immune response and lower infection rate than ePTFE grafts, yet permeability rate was 18% (< than ePTFE)12 months after implantation |
| MatrACELL®: decellularized ECM ( | Decellularized human pulmonary artery patch | Anionic detergent, N-Lauroyl sarcosinate, and endonuclease | Pulmonary valve replacement | Retained biomechanical properties, biocompatible, and able to support cellular and vascular in-growth |
| ProCol®: bovine mesenteric vein ( | Glutaraldehyde cross-linked bovine mesenteric vein; ID: 6 mm; length: 10–40 cm | A bridge graft for vascular access | Synthetic vascular grafts for patients who have at least one-time failed graft access | Improve pulsatile forward flow, durability, anastomotic compliance, minimal bleeding, and good degree of biocompatible |
| Solcograft®: bovine carotid artery ( | Decellularized carotid artery cross-linked with adipyl dichloride | Vascular conduits for pediatric and adult use | Aortic, aortoiliac, carotid and vena cava replacement | Increased biochemical properties, no aneurysm, reduced infection and early thrombosis, and homogenous structure before and after implantation |
| SynerGraft®: cadaver saphenous/femoral veins ( | Dimethyl sulfoxide-cryopreserved cadaver veins: Saphenous vein ID: 3–6 mm; length: 20–80 cm; Femoral vein ID: 6–15 mm; length: 10–30 cm | Saphenous vein bypass below knee in patients with infected fields that can’t generate fistulas | Arteriovenous access line, and bypass below knees for patients with infected fields and/or at risk of infection | Excellent durability and hemodynamics, and virtually eliminates presence of allogenic donor cells to maintain matrix structural integrity and need for anticoagulation |
FIGURE 1Structures of major native small- to large-caliber blood vessels.
FIGURE 2Key elements and approaches to support the development of decellularized vascular grafts: (A) basic decellularization vessel model that can be tuned with various additives (B) using combinative approaches to generate improved vascular substitutes.